Yes, there seems to be a connotation of leaning away from PMD. In which case, EMA trial initially. ICP reduction is the key to presendin and the the other pressure indications which are larger in market scale. Sure, we need approval for IIH though this is the orphan vehicle to markets we should be more interested in.
IMO.
Yes, there seems to be a connotation of leaning away from PMD....
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
